Document is current
Any future updates will be listed below
-
Authors
Fidyt, Klaudyna
Pastorczak, Agata
Cyran, Julia
Crump, Nicholas T. https://orcid.org/0000-0001-9610-6763
Goral, Agnieszka https://orcid.org/0000-0002-7324-9718
Madzio, Joanna
Muchowicz, Angelika https://orcid.org/0000-0003-4707-1722
Poprzeczko, Martyna https://orcid.org/0000-0002-8703-5614
Domka, Krzysztof
Komorowski, Lukasz
Winiarska, Magdalena
Harman, Joe R. https://orcid.org/0000-0003-3668-1859
Siudakowska, Karolina
Graczyk-Jarzynka, Agnieszka
Patkowska, Elzbieta https://orcid.org/0000-0001-8691-4310
Lech-Maranda, Ewa
Mlynarski, Wojciech https://orcid.org/0000-0003-2714-5851
Golab, Jakub https://orcid.org/0000-0002-2830-5100
Milne, Thomas A. https://orcid.org/0000-0002-0413-4271
Firczuk, Malgorzata https://orcid.org/0000-0002-1719-5233
-
Funding
Funding for this research was provided by:
Narodowe Centrum Nauki (2015/18/E/NZ5/00723, 2018/31/N/NZ5/01438, 2019/32/T/NZ5/00241)
RCUK | Medical Research Council (MC_UU_00016/6, MC_UU_00016/6, MC_UU_00016/6)
RCUK | Engineering and Physical Sciences Research Council (EP/R513295/1, EP/R513295/1, EP/R513295/1)
Ministerstwo Nauki i Szkolnictwa Wyższego (013/RID/2018/19)
- License Information
-
More Information
Article History
Received: 3 February 2021
Revised: 2 January 2022
Accepted: 18 January 2022
First Online: 28 January 2022
Competing interests
: TAM is a founding shareholder of OxStem Oncology (OSO), a subsidiary company of OxStem Ltd. TAM and NTC are both founding shareholders and paid consultants for Sandymount Therapeutics (a subsidiary company of Dark Blue Therapeutics). The other authors have no competing financial interests to declare.
